Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 04 2024 - 4:00PM
Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology
company developing novel, investigational engineered cytokine
therapies designed to address areas of unmet need for patients with
a variety of cancers, today announced that on June 3, the Company
granted to two newly hired employees (i) non-statutory stock
options to purchase an aggregate of 7,995 ordinary shares of the
Company and (ii) restricted stock units with respect to an
aggregate of 4,305 ordinary shares of the Company, pursuant to the
Company’s 2024 Inducement Stock Option and Incentive Plan, each as
an inducement material to the new employees entering into
employment with the Company in accordance with Nasdaq Listing Rule
5635(c)(4).
The stock options have an exercise price of $3.41 per share,
which is equal to the closing price per share of the Company’s
ordinary shares as reported by Nasdaq on June 3, 2024. The options
have a ten-year term and vest over four years, with 25% of the
original number of shares vesting on the first anniversary of the
grant date and 6.25% of the shares underlying the options vesting
quarterly thereafter, subject to such employee’s continued service
with the Company through the applicable vesting dates. Each of the
stock options is subject to the terms and conditions of a stock
option award agreement covering the grant and the Company’s 2024
Inducement Stock Option and Incentive Plan. The restricted stock
units vest over four years, 25% per year on the anniversary of the
grant date, subject to such employee’s continued service with the
Company through the applicable vesting dates. Each of the
restricted stock units is subject to the terms and conditions of a
restricted stock award agreement covering the grant and the
Company’s 2024 Inducement Stock Option and Incentive Plan.
About Mural OncologyMural Oncology is
leveraging its novel protein engineering platform to develop
cytokine-based immunotherapies for the treatment of cancer. By
combining our expertise in cytokine biology and immune cell
modulation and our protein engineering platform, we are developing
medicines to deliver meaningful and clinical benefits to people
living with cancer. Our mission is to broaden the potential
and reach of cytokine-based immunotherapies to improve the lives of
patients. Our lead candidate, nemvaleukin, is currently in
potentially registrational trials in mucosal melanoma and
platinum-resistant ovarian cancer. Mural Oncology has its
registered office in Dublin, Ireland, and its primary facilities in
Waltham, Mass. For more information, visit Mural Oncology’s website
at www.muraloncology.com and follow us on LinkedIn and X.
Contacts
Investors:David Borah,
CFAdavid.borah@muraloncology.com 781-614-0060
Media:Katie
Sullivankatie.sullivan@muraloncology.com781-614-0034
Mural Oncology (NASDAQ:MURA)
Historical Stock Chart
From Jul 2024 to Aug 2024
Mural Oncology (NASDAQ:MURA)
Historical Stock Chart
From Aug 2023 to Aug 2024